Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis
Major non‐GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes onlyRR 0.84 [0.42, 1.68]4 studies · 1838 participantsVery low